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Abstract
Decreased expression of dopamine D2 receptors (D2R), dysfunction of inhibitory neurotransmission and impairments in
the structure and connectivity of neurons in the medial prefrontal cortex (mPFC) are involved in the pathogenesis of
schizophrenia and major depression, but the relationship between these changes remains unclear. The polysialylated
form of the neural cell adhesion molecule (PSA-NCAM), a plasticity-related molecule, may serve as a link. This molecule
is expressed in cortical interneurons and dopamine, via D2R, modulates its expression in parallel to that of proteins
related to synapses and inhibitory neurotransmission, suggesting that D2R-targeted antipsychotics/antidepressants
may act by affecting the plasticity of mPFC inhibitory circuits. To understand the role of PSA-NCAM in this plasticity, rats
were chronically treated with a D2R agonist (PPHT) after cortical PSA depletion. PPHT-induced increases in GAD67 and
synaptophysin (SYN) neuropil expression were blocked when PSA was previously removed, indicating a role for PSA-
NCAM in this plasticity. The number of PSA-NCAM expressing interneuron somata also increased after PPHT treatment,
but the percentages of these cells belonging to different interneuronal subpopulations did not change. Cortical
pyramidal neurons did not express PSA-NCAM, but puncta co-expressing this molecule and parvalbumin could be
found surrounding their somata. PPHT treatment increased the number of PSA-NCAM and parvalbumin expressing
perisomatic puncta, but decreased the percentage of parvalbumin puncta that co-expressed SYN. PSA depletion did not
block these effects on the perisomatic region, but increased further the number of parvalbumin expressing puncta and
increased the percentage of puncta co-expressing SYN and parvalbumin, suggesting that the polysialylation of NCAM
may regulate perisomatic inhibition of mPFC principal neurons. Summarizing, the present results indicate that
dopamine acting on D2R influences structural plasticity of mPFC interneurons and point to PSA-NCAM as a key player in
this remodeling.
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Introduction
During recent years, several evidences indicate that, in
addition to neurochemical alterations, changes in the structure
and connectivity of neurons in the medial prefrontal cortex
(mPFC) may also underlie the pathogenesis of different
psychiatric disorders, including schizophrenia and major depres-
sion [1–2]. Dopamine and serotonin play a crucial role in the
regulation of mPFC function and in the etiology and treatment of
these disorders. Moreover, there is evidence indicating that
changes in monoamine neurotransmission can induce neuronal
structural remodeling in the adult CNS. Although most of the
studies on neuronal structural plasticity have been focused on
principal neurons, there is abundant evidence that, in these
psychiatric disorders, interneurons and cortical inhibitory net-
works show abnormalities [3–5]. The polysialylated form of the
neural cell adhesion molecule (PSA-NCAM) is a good candidate
to mediate these structural changes, especially in interneurons.
The addition of long chains of polysialic acid to NCAM confers
anti-adhesive properties, which favor plastic processes such as
neuronal migration and the growth or remodeling of neurites,
spines and synapses [6–8]. In rodents, the expression of PSA-
NCAM is very high during embryonic and early postnatal
development but subsequentially decreases. However, expression
of this molecule can be still observed in the adult mPFC and
persists stable until old age [9–10]. In this cortical region, PSA-
NCAM is exclusively expressed by a subset of interneurons and it
is found in their somata and in inhibitory elements in the neuropil
[9]. These interneurons have reduced dendritic arborization,
spine density and less synaptic input than interneurons lacking
PSA-NCAM [11]. Our laboratory has described that manipula-
tion of dopaminergic or serotoninergic neurotransmission in the
mPFC of adult rats leads to changes in the expression of PSA-
NCAM [12–13]. Dopamine-induced changes may probably take
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expressed in PSA-NCAM expressing interneurons of the mPFC,
since D2R agonists, such as 2-(N-Phenethyl-N-propyl) amino-5-
hydroxytetralin hydrochloride (PPHT), increased PSA-NCAM
expression and D2R antagonists (haloperidol) decreased it.
Interestingly, this modulation of PSA-NCAM expression occurs
in parallel to changes in the expression of synaptic proteins and
molecules related to inhibitory neurotransmission, which strongly
suggests the involvement of PSA-NCAM in the plasticity of
prefrontocortical inhibitory circuits [12].
In order to better understand the influence of dopamine
through D2R and PSA-NCAM in the structural plasticity of the
mPFC, we have replicated our experiment using PPHT [12] in
rats in which PSA had been previously depleted from the mPFC
using the specific enzyme Endo-N-acetylneuraminidase (Endo-N).
We have studied whether PPHT-induced changes in synaptic
proteins and molecules related to inhibitory neurotransmission
could be blocked by PSA depletion, as well as the effects of PPHT
and Endo-N on the perisomatic innervation of pyramidal neurons
in the mPFC. The effects of PPHT on the number and
neurochemical phenotype of PSA-NCAM expressing somata in
this region have also been studied.
Materials and Methods
Ethics statement
All animal experimentation was conducted in accordance with
the Directive 2010/63/EU of the European Parliament and of the
Council of 22 September 2010 on the protection of animals used
for scientific purposes and was approved by the Committee on
Bioethics of the Universitat de Vale `ncia (permit number:
A1234271133556). Every effort was made to minimize the
number of animals used and their suffering.
Animals
Adult male Sprague-Dawley rats (3 months-old; 296613 g;
Harlan Interfauna Iberica S.L., Barcelona, Spain) were used for all
experimental procedures. Twenty-four rats (6 rats in each of the 4
experimental groups) were used to study the effects of D2R agonist
chronic treatment after specific polysialic acid (PSA) depletion
from the mPFC (see next section) and four rats to analyze the
neurochemical phenotype of PSA-NCAM expressing puncta
surrounding pyramidal cell somata.
Animals were housed in groups of 3 in a temperature- and
humidity-controlled environment and maintained on a 12 h light/
dark cycle with food and water available ad libitum. Rats were
allowed to habituate to our facilities one week prior to the start of
the experiments.
Polysialic acid depletion and D2R agonist chronic
treatment
Twenty-four rats (6 rats in each of the 4 experimental groups)
were unilaterally injected in the secondary motor cortex with 1 ml
of either the enzyme Endo-N (AbCys, Paris, France) or a vehicle
solution and, one week later, they were treated for 7 days with
either PPHT or saline as described before [12]. Body weight was
measured on the day of surgery (day 0) and in days 7, 10 and 14.
Please, see table S1 and material and methods for a detailed
explanation on the procedures and body weight statistical analysis.
Histological procedures
Rats were perfused transcardially with 4% paraformaldehyde
solution for 30 min. Brains were extracted from the skull and their
hemispheres were separated.
Both hemispheres of control rats (n=4) and the ipsilateral
hemispheres respective to the side of injection of experimental rats
(n=24) were cut in coronal sections (50 mm) and then, the slices
were collected in 10 sequential subseries.
More details on the histological procedures used can be found in
material and methods S1.
Immunohistochemistry for conventional light
microscopy
In order to analyze whether Endo-N injection and/or PPHT
treatment induced changes on the neuropil expression of PSA-
NCAM, SYN, GAD67 and NCAM, four subseries from each
animal were processed ‘‘free-floating’’ for immunohistochemistry
using the avidin-biotin-peroxidase (ABC) method as described
before [9,12]. The detailed procedure can be found in material
and methods S1. For further information on the antibodies
used, see table 1.
PSA-NCAM immunohistochemistry was also used to analyze
the number of PSA-NCAM expressing interneurons after PPHT
treatment and to validate the effectiveness of Endo-N treatment.
Quantification of neuropil immunoreactivity and
estimation of the total number of neurons expressing
PSA-NCAM, CB, CR or PV
In animals treated with Endo-N and/or PPHT, the intensity of
PSA-NCAM, SYN, GAD67 and NCAM immunoreactivities in
the mPFC neuropil were determined using a previously described
methodology [9,12–14].
The number of PSA-NCAM expressing interneurons in the
different layers and regions of mPFC was estimated using a
modified version of the fractionator method [15], as described
before [13,16].
See material and methods S1 and figure S3 for further
details on methodology and statistical analysis.
Immunohistochemistry for confocal microscopy
Fifty mm-thick coronal sections were processed ‘‘free-
floating’’ for immunohistochemistry as described before
[11,12]. See table 1 and material and methods S1 for
further details on antibodies, specificity and immunohisto-
chemical procedures.
In order to analyze the neurochemical phenotype of PSA-
NCAM expressing puncta surrounding pyramidal neuron somata
in control animals, we performed seven different triple immuno-
stainings: anti-PSA-NCAM and anti-a subunit of the Ca
2+/
calmodulin dependent protein kinase II (CaMKII-a) primary
antibodies in combination with (1) anti-GAD65/67, (2) anti-
vesicular GABA transporter (VGAT), (3) anti-VGLUT1, 4) anti-
SYN, 5) anti-parvalbumin (PV), 6) anti-calretinin (CR) or (7) anti-
calbindin (CB) antibodies.
In sections obtained from experimental rats, we performed a
triple immunostaining against PSA-NCAM, PV and CB, and a
double immunostaining against PSA-NCAM and CR, to analyze
the neurochemical phenotype of PSA-NCAM expressing inter-
neurons after PPHT treatment and to estimate the number of
interneurons expressing CB, CR or PV in the different regions of
the mPFC (using a modified version of the fractionator method)
[13,15,16].
In order to study the perisomatic innervation of mPFC
pyramidal neurons after treatment, we performed two double
and a triple immunostaining using anti-CaMKII-a primary
antibody in combination with either (1) anti-PSA-NCAM, (2)
anti-GAD65/67 or (3) anti-PV and anti-SYN primary antibodies.
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expressing interneurons after PPHT treatment
Sections double or triple labeled for PSA-NCAM and
interneuronal subpopulation markers (PV, CB, CR) were
observed under a confocal microscope (Leica TCS-SPE) using a
636 oil objective. Z-series of optical sections (1 mma p a r t )w e r e
obtained using sequential scanning mode and stacks were then
processed with Zeiss LSM 5 image software. Fifty PSA-NCAM
immunoreactive neurons within the mPFC were randomly
selected from each animal and immunostained to determine the
co-expression of PSA-NCAM and each marker. Percentages of
co-localization were determined for each animal and means 6
S.E.M. were calculated. The resulting values (Control/PPHT vs
Control/Control) were subjected to unpaired Student’s t-test
statistical analysis.
Analysis of the neurochemical phenotype of PSA-NCAM
immunoreactive puncta surrounding pyramidal cell
somata
Sections processed for fluorescent immunohistochemistry were
observed under a confocal microscope (Leica TCS-SPE) using a
636 oil objective. From each animal, 50 CaMKII-a expressing
neurons from mPFC layers III and V displaying triangular-shaped
soma were randomly selected from all the sections containing this
cortical region (8–10 sections between Bregma +3,20 mm to
21,40 mm [17]). These cells were first identified using conven-
tional fluorescence microscopy and then, Z-series of optical
sections (0.5 mm apart) covering all its three-dimensional extension
were acquired using sequential scanning mode. Stacks were
processed with Zeiss LSM 5 Image Browser software at 46-Zoom
magnification. The soma profile of these neurons was drawn and
puncta placed within an area 0.5 mm distal from the edge of this
profile were analyzed. Puncta were defined as having an area not
smaller than 0.15 and not larger than 2.5 mm
2 [18]. The co-
localization of PSA-NCAM and each of the different markers
(GAD65/67, VGAT, VGLUT1, SYN, PV, CB and CR) was
analyzed on five consecutive confocal planes from each selected
neuron, in which the penetration of both antibodies was optimal.
The percentage of puncta co-expressing PSA-NCAM and each
marker was obtained for each neuron and mean 6 S.E.M was
determined. Puncta density values were also determined for each
marker and expressed as number of puncta per micron of soma
perimeter.
Table 1. Primary and secondary antibodies.
Primary antibodies
(abbreviated names)
Host Isotype Dilution Incubation Company References
Anti-CB Rabbit IgG 1:2000 O/N, 25uC Swant He ´dou et al. 2002
Anti-CR Rabbit IgG 1:2000 O/N, 25uC Swant Schwaller et al., 1993
Anti-CaMKII-a Mouse IgG1 1:500 36 h, 4uC Abcam Benson et al., 1992
Anti-GAD67 Mouse IgG2a 1:500 O/N, 25uC Chemicon-Millipore Varea et al., 2005
Anti-GAD65/67 Rabbit IgG 1:1000 O/N, 25uC Chemicon-Millipore Benagiano et al., 2007
Anti-NCAM Mouse IgG2b 1:200 O/N, 25uC DSHB dshb.biology.uiowa.edu
Anti-PSA-NCAM Mouse IgM 1:700 36 h, 4uC Abcys Theodosis et al, 1991
Anti-PV
(1) Rabbit IgG 1:2000 O/N, 25uC Swant Miettinen et al., 1996
Anti-PV Guinea pig IgG 1:2000 36 h, 4uC Synaptic Systems www.sysy.com
Anti-SYN
(2) Mouse IgG1 1:500 O/N, 25uC Sigma-Aldrich Devoto and Barnstable, 1989
Anti-SYN Rabbit IgG 1:1000 O/N, 25uC Chemicon-Millipore Hanaya et al., 2007
Anti-VGAT Rabbit IgG 1:1000 O/N, 25uC Synaptic Systems Takamori et al.,2000
Anti-VGLUT1 Guinea pig IgG 1:2000 O/N, 25uC Chemicon-Millipore Melone et al., 2005
Secondary antibodies
Host Label Dilution Incubation Company
Anti-Guinea pig IgG Donkey Cy
TM5 1:400 1 h, 25uC Jackson immunoResearch
Anti-Mouse IgM Donkey Biotin-SP 1:400 1 h, 25uC Jackson immunoResearch
Anti-Mouse IgM Goat Alexa FluorH 555 1:400 1 h, 25uC Molecular Probes
Anti-Mouse IgG Donkey Biotin-SP 1:400 1 h, 25uC Jackson immunoResearch
Anti-Mouse IgG1
(3) Goat Biotin-SP 1:400 1 h, 25uC Jackson immunoResearch
Anti-Rabbit IgG Donkey Alexa FluorH 488 1:400 1 h, 25uC Molecular Probes
Anti-Rabbit IgG Donkey Alexa FluorH 647 1:400 1 h, 25uC Molecular Probes
(1)Used in CaMKIIa - PSA-NCAM - PV triple immunohistochemistry.
(2)Used in SYN immunohistochemistry for light microscopy.
(3)Used in multiple-labeling experiments for the detection of anti-CaMKII-a primary antibody when other primary antibody generated in mouse was also being used. The
Avidin, NeutrAvidinH, Texas RedH conjugate (1:200, Molecular Probes) or streptavidin, Alexa Fluor H 488 conjugate were used before to detect biotin.
Abbreviations: CB, calbindin-D28k; CR , calretinin; CaMKII-a, a subunit of the Ca
2+/calmodulin dependent protein kinase II; GAD67, 67 kDa isoform of the glutamate
decarboxilase enzime, GAD65/67, both 65 and 67 kDa isoforms of the glutamate decarboxilase enzyme; PSA-NCAM, polysialylated form of de neural cell adhesion
molecule; PV, parvalbumin; SYN, synaptophysin; VGAT, vesicular c-aminobutyric acid (GABA) transporter; VGLUT1, vesicular glutamate transporter 1.
doi:10.1371/journal.pone.0029516.t001
D2R & PSA-NCAM Modulate mPFC Structural Plasticity
PLoS ONE | www.plosone.org 3 December 2011 | Volume 6 | Issue 12 | e29516Quantification of perisomatic puncta on mPFC pyramidal
neurons
Sections processed for (1) CaMKII-a - PSA-NCAM, (2)
CaMKII-a- GAD65/67 or (3) CaMKII-a - PV - SYN
immunohistochemistries were observed and analyzed as described
above, with some minor differences. In this case, six pyramidal
neurons per animal from mPFC layers III and V were randomly
selected from all sections containing this region and from each
immunostaining. A total of 144 neurons were analyzed for each
immunostaining.
Values of puncta density for PSA-NCAM, GAD65/67, PV and
SYN were obtained from each neuron and expressed as number of
puncta per micron of soma perimeter. For each experimental
group, mean 6 S.E.M. was determined and the resulting values
were analyzed by unpaired Student’s t-test (for the density of PSA-
NCAM expressing puncta) or by one-way ANOVA, with the
number of neurons as the ‘‘n’’. Significant differences were further
analyzed by Student-Newman-Keuls post-hoc test. The percent-
age of PV puncta co-expressing SYN was also obtained from each
neuron and analyzed following the same procedure.
Summary of statistical methods
For body weight analysis, body weight differences across the
different time points (day 0, 7, 10 and 14) were subjected to one-
way ANOVA tests followed, when appropriate, by multiple pair-
wise comparisons with Bonferroni’s correction (see material and
methods S1 and table S1).
In order to quantify PSA-NCAM, GAD67, SYN and NCAM
neuropil immunoreactivities, optical densities were analyzed by
one-way repeated measures ANOVA tests, where ‘‘region’’
(infralimbic, prelimbic, dorsal cingulate and ventral cingulate
cortices) and ‘‘layer’’ (I, II, III, V, VI) were considered as within-
subjects variables (repeated measures variables) and treatment
(Endo-N/PPHT, Endo-N/Control Control/PPHT, Control/
Control), as between-subjects variable (see materials and methods
S1).
To analyze the differences on the total number of neurons
expressing PSA-NCAM, CB, CR or PV between Control/Control
and Control/PPHT groups, data were subjected to unpaired
Student’s t-test analysis.
In order to study whether PPHT treatment-induced differences
on the neurochemical phenotype of PSA-NCAM expressing
interneurons, the percentages of co-localization of PSA-NCAM
with CB, CR or PV were determined for each animal from
Control/Control and Control/PPHT group. Data were then
subjected to unpaired Student’s t-test analysis.
To analyze the differences on perisomatic innervation of mPFC
pyramidal neurons after treatment, values of puncta density for
PSA-NCAM, GAD65/67, PV and SYN and the percentages of
PV puncta co-expressing SYN were obtained from each neuron (6
neurons from each of the 6 animals of the 4 experimental groups)
and then analyzed by unpaired Student’s t-test (for the density of
PSA-NCAM expressing puncta) or by one-way ANOVA, with the
number of neurons as the ‘‘n’’. Significant differences were further
analyzed by Student-Newman-Keuls post-hoc test.
Results
Body weight loss after PPHT treatment
From the day of surgery (day 0) to the onset of pharmacological
treatment (day 7), no statistically significant differences were found
on body weight between groups (p=0.087). After PPHT
treatment (from 7
th to 14
th day), animals showed a significant
weight loss when compared with non-PPHT treated ones (Endo-
N/PPHT vs. Endo-N/Control: p,0.0001; Control/PPHT vs.
Control/Control: p=0.0246). These decreases on body weight
took place specifically from 7
th to 10
th day (Endo-N/PPHT vs.
Endo-N/Control: p,0.0001; Control/PPHT vs. Control/Con-
trol: p=0.005); from day 10
th to 14
th, all groups increased equally
their body weight (p=0.322). Please, see table S1 for detailed
information.
PSA-NCAM expressing elements in the mPFC: Pyramidal
neuron somata in the mPFC are surrounded by puncta
co-expressing inhibitory or synaptic markers
PSA-NCAM expression was found in three types of structures of
the mPFC: (1) neuronal somata, (2) puncta in the neuropil, and (3)
puncta surrounding the somata of pyramidal neurons.
Since PPHT modulates the expression of PSA-NCAM and
molecules related to inhibitory neurotransmission in the mPFC
and since many inhibitory contacts are established on the
perisomatic region of pyramidal cortical neurons, we analyzed
the presence and the phenotype of PSA-NCAM expressing puncta
in this region.
PSA-NCAM expressing puncta were found surrounding the
somata of mPFC pyramidal neurons with a mean density of
0.36860.014 puncta/mm( table 2, figs. 1 & 2). These puncta
mainly co-expressed markers of inhibitory elements or synapses,
such as GAD65/67 (36.07362.704%; table 2, fig. 1 A)o r
VGAT (38.36361.005%; table 2, fig. 1 B) and rarely co-
expressed VGLUT1 (2.54560.461%; table 2, fig. 1 C), a
marker of excitatory synapses. The synaptic vesicle protein SYN
was also frequently found in PSA-NCAM expressing puncta
(34.33861.858%; table 2, fig. 1 D).
Because PSA-NCAM expressing perisomatic puncta were
shown to be mainly inhibitory, the co-expression in these puncta
of the interneuron subpopulation markers PV, CR and CB was
also studied. This analysis revealed that the highest percentage of
co-localization occurred with PV (40.62161.469%; table 2, fig. 2
A), whereas the co-localization with CR (2.89060.087%; table 2,
fig. 2 B) or CB (2.41560.039%; table 2, fig. 2 C) was very low.
The density of PV expressing perisomatic puncta was also
substantially higher than that of puncta expressing CB or CR
(see table 2).
All the results shown in the following sections have been
summarized in table 3.
PPHT treatment increases the number of interneurons
expressing PSA-NCAM, CB, CR and PV in the mPFC,
without affecting the neurochemical phenotype of
PSA-NCAM expressing interneurons
The number of PSA-NCAM expressing interneuron somata in
the mPFC was higher in PPHT-treated animals than in non-
treated ones (p=0.0004) (figs. 3A & D). In particular, statistically
significant differences were observed in layers III, V and VI of
infralimbic, prelimbic, dorsal cingulate and ventral cingulate
cortices (fig. S1).
The number of interneuron somata belonging to different
interneuron subpopulations (defined by the expression of the
calcium-binding proteins CB, CR and PV) was also increased after
PPHT treatment in the mPFC (p,0.0001 for CB, p=0.0044 for
CR and p,0.0001 for PV) (figs. 3B). The same effect can also be
observed in every region within the mPFC (see fig. S2 for further
information about means and p-values).
Nevertheless, the percentages of PSA-NCAM expressing
interneuron somata belonging to these interneuron subpopulations
did not change after PPHT treatment (p.0.05 in all comparisons;
D2R & PSA-NCAM Modulate mPFC Structural Plasticity
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(74.062.6% in control group, 75.364.7% in PPHT treated group;
figs. 3 C & E) and much lower percentages co-expressed CR
(3.760.8% in control group, 4.561.7% in PPHT treated group;
figs. 3 C & F) or PV (1.760.8% in control group, 1.060.6% in
PPHT treated group; figs. 3 C & G).
Endo-N injection blocks PPHT-induced increases in SYN
and GAD67 expression in the mPFC neuropil, while
NCAM expression is not affected by any of the
treatments
For the neuropil expression of PSA-NCAM, SYN and GAD67,
repeated-measures ANOVA test showed significant main effects of
treatment (PSA-NCAM: F3,14=194.843, p,0.001; SYN:
F3,12=8.665,p=0.003;GAD67:F3,11=36.306, p,0.001;NCAM:
F3,15=1.007, p=0.001), region (PSA-NCAM: F1.935,27.089=
13.89, p,0.001; SYN: F3,36=3.821, p=0.018; GAD67:
F1.644,18.086=12.014, p=0.001) and layer (PSA-NCAM:
F1.120,15.685=63.136, p,0.001; SYN: F4,9=176.617, p,0.001;
GAD67: F1.367,15.061=178.867, p,0.001), so multiple pair wise-
comparisons with Bonferroni’s correction were performed for each
immunostaining in order to compare treatment effect on the mPFC
neuropil expression between pairs of experimental groups. Howev-
er, for the neuropil expression of NCAM, repeated-measures
ANOVA test showed significant main effects of region
(F1.855,31.539=12.412, p,0.0001) and layer (F1.979,33.635=
255.993, p,0.0001) but not treatment (F3,15=1.007, p=0.417).
Regarding treatment effect and, in consonance with our
previous results [12], 7 days of PPHT treatment induced
statistically significant increases in PSA-NCAM (p,0.001; fig. 4
a, b & e), SYN (p=0.003; fig. 4 f, g & j) and GAD67 (p,0.001;
fig. 4 k, l & o) expression in the mPFC neuropil. These effects of
PPHT on SYN and GAD67 expression were prevented when PSA
was removed one week before the onset of the PPHT treatment
[Control/Control vs. Endo-N/PPHT: p=1.000 (SYN), p=0.139
(GAD67); Endo-N/Control vs. Endo-N/PPHT: p=1.000 (SYN
and GAD67)] (fig. 4 h-j & m–o). PSA-NCAM expression in the
mPFC remained undetectable 14 days after Endo-N injection
(fig. 4 c–e).
Endo-N administration by itself did not induce changes in
GAD67 or SYN expression in the mPFC neuropil [Endo-N/
Control vs. Control/Control: p=1.000 for GAD67 and SYN]
(fig. 4 j & o).
NCAM expression in the mPFC neuropil was not affected by
any of the treatments [Control/Control vs. Control/PPHT:
p=1.000; Control/Control vs. Endo-N/Control: p=1.000;
Control/Control vs. Endo-N/PPHT: p=0.643; Control/PPHT
vs. Endo-N/PPHT: p=1.000] (fig. 4 p–t).
Three-way interaction (region6layer6treatment) on the
repeated measures ANOVA test was also significant (p,0.05) for
the neuropil expression of PSA-NCAM, SYN and GAD67 but not
for NCAM (PSA-NCAM: F11.716,54.675=2.626, p=0.008; SYN:
F12,3=11.002, p=0.036; GAD67: F14.621,53.610=2.021, p=
0.032; NCAM: F13.680,77.519=0.794, p=0.670), so multiple pair-
Table 2. Puncta surrounding pyramidal neurons somata.
Puncta immunoreactive for: Puncta density (puncta/mm)











PSA-NCAM – GAD65/67 0.09360.018 36.07362.704
PSA-NCAM – VGAT 0.18460.006 38.36361.005
PSA-NCAM – VGLUT1 0.00460.001 2.54560.461
PSA-NCAM – SYN 0.16360.013 34.32861.858
PSA-NCAM – CB 0.01060.001 2.41560.039
PSA-NCAM – CR 0.01060.001 2.89060.087
PSA-NCAM –PV 0.17960.004 40.62161.469
GAD65/67 – PSA-NCAM 0.09360.018 28.11462.891
VGAT – PSA-NCAM 0.18460.006 32.94860.869
VGLUT1 – PSA-NCAM 0.00460.001 1.92360.423
SYN –PSA-NCAM 0.16360.013 26.83160.908
CB – PSA-NCAM 0.01060.001 42.97763.690
CR – PSA-NCAM 0.01060.001 20.62461.122
PV – PSA-NCAM 0.17960.004 43.33163.622
(a)Puncta density data are expressed as mean 6 s.e.m. of puncta expressing the named marker/s per micron of soma perimeter.
(b)Co-localization percentage of puncta expressing the first named marker which also expresses the second or second and third named marker/s (i.e. PSA-NCAM –
GAD65/67 co-localization percentage: percentage of PSA-NCAM expressing puncta which also express GAD65/67). Data are expressed as mean6 s.e.m.
doi:10.1371/journal.pone.0029516.t002
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only for PSA-NCAM, SYN and GAD67, in order to analyze in
which specific layer from each region inside the mPFC there were
differences between groups. The results indicate that the same
effects described above for PSA-NCAM, SYN and GAD67
expression, considering the whole mPFC neuropil, can also be
observed in most layers of every region within the mPFC
(infralimbic, prelimbic, dorsal cingulate and ventral cingulate
cortices) (see figs. S4, S5, S6, for further information about
means and p-values).
Effects of PPHT and Endo-N treatments on perisomatic
puncta of mPFC pyramidal neurons
PPHT treatment increases the density of PSA-NCAM
expressing perisomatic puncta. PPHT treatment induces a
statistically significant 123.8% increase in the density of PSA-
NCAM expressing puncta surrounding pyramidal neuron somata
(p=0.0023; fig. 5 a–c), which is in line with the effects described
above in PSA-NCAM expressing somata and neuropil puncta.
PPHT and/or Endo-N treatments increase the density of
inhibitory perisomatic puncta. Both PPHT and Endo-N
Figure 1. Confocal microscopic analysis of the neurochemical phenotype of PSA-NCAM immunoreactive puncta surrounding
pyramidal cell somata in mPFC. (A) PSA-NCAM-expressing puncta co-localizing with GAD67 in the perisomatic region of CaMKII-a expressing
neurons. (B) PSA-NCAM/VGAT double-labeled puncta surrounding CaMKII-a immunoreactive neurons. (C) Lack of co-localization between perisomatic
PSA-NCAM-expressing puncta and VGLUT1-expressing puncta. (D) Perisomatic puncta co-expressing PSA-NCAM and SYN. All the images in this figure
are taken from single confocal planes. Scale bar: 10 mm. Insets in the images are 56enlargements of puncta marked with arroheads.
doi:10.1371/journal.pone.0029516.g001
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significant increases (p,0.0001 in all cases) in the density of
GAD65/67 (33.2% and 82.54%, respectively; fig. 5 d–h) and PV
(19.2% and 38.59%, respectively fig. 5 i–m) expressing puncta in
the perisomatic region of pyramidal neurons. However, the
combination of both treatments induced statistically significant
but lower increases than those observed after Endo-N treatment
alone (45.8% increase, p,0.0001 for GAD65/67; 23.8% increase,
p,0.0001 for PV; figs. 5 g–h & l–m).
Endo-N, by itself or administered before PPHT
treatment, increases the density of SYN perisomatic
puncta. Endo-N administration by itself induced a statistically
significant 30.5% increase in the density of SYN expressing puncta
surrounding pyramidal neuron somata (p,0.0001). Increases were
even higher when PPHT was administered after Endo-N injection
(44.7% increase; p,0.0001 compared with Control/Control;
p=0.0008 compared with Endo-N/Control). By contrast, PPHT
treatment alone did not change the density of SYN perisomatic
puncta (p=0.6660) (fig. 5 n–r).
PPHT decreases and Endo-N increases the percentage of
PV perisomatic puncta co-expressing SYN. After PPHT
treatment, 21.2060.53% of PV expressing puncta surrounding
pyramidal neuron somata were found to co-express SYN, which
implied a small but significant decrease of this percentage
(p,0.0001) when compared with that of the control group
(32.8260.56%). Conversely, Endo-N administration induced a
statistically significant increase of this percentage, reaching
48.1660.99% (p,0.0001). When Endo-N was administered
before PPHT treatment, 44.7260.65% of PV puncta co-
expressed SYN, a percentage significantly lower than that of
Endo-N/Control group (p=0.0006) but still higher than that of
the Control/Control group (p,0.0001) (fig. 5 s–w).
Figure 2. Confocal microscopic analysis of the co-expression of PV, CR and CB in PSA-NCAM immunoreactive puncta surrounding
pyramidal cell somata in mPFC. (A) PSA-NCAM-expressing puncta co-expressing with PV in the perisomatic region of a neuron expressing
CaMKII-a. (B) PSA-NCAM immunoreactive puncta co-expressing CR surrounding CaMKII-a expressing neurons. (C) Observe a CB-expressing puncta
close to a PSA-NCAM expressing puncta in the perisomatic region of a pyramidal neuron. All the images in this figure are taken from single confocal
planes. Scale bar: 10 mm. Insets in the images are 56enlargements of puncta marked with arrowheads.
doi:10.1371/journal.pone.0029516.g002
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Effects of D2R agonist treatment on mPFC neuronal
circuitry
Our results are in accordance with previous findings demon-
strating that chronic PPHT treatment increases GAD67 and
SYN expression [12] and synaptic density [19] in the mPFC.
These effects are probably mediated by dopamine through D2R,
because D2R antagonists and dopamine depletion produce
opposite effects [12]. The PPHT-induced upregulation of
GAD67 expression in the neuropil probably reflects an increase
in the number of inhibitory synapses on pyramidal neurons, since
the number of puncta expressing these GABA-synthesizing
enzymes also increases in the and perisomatic region of these
cells. A direct effect of PPHT on these inhibitory structures is
likely, because D2R are expressed in interneurons [20] and
activation of D2R attenuates excitatory synaptic transmission in
the adult PFC, involving GABA release by local inhibitory cells
[21]. It is possible that this activation occurs mainly on basket
interneurons, because D2R are particularly abundant in these
cells [22] and specific agonists of D2R activate them [23].
Supporting this hypothesis, we have also detect an increase in the
density of puncta expressing PV, a calcium binding protein
expressed by many fast spiking/basket interneurons, in the
perisomatic region of pyramidal neurons.
Our results on the effects of PPHT may have implications in the
understanding of the molecular bases of schizophrenia and major
depression, since decreased levels of dopamine [24,25] and D2R
[26,27], as well as deficits in GABAergic neurotransmission and
PV expressing interneurons have been found in the PFC of
patients and animal models of these disorders [28,29].
Effects of PPHT on PSA-NCAM expression
PSA-NCAM expression in the mPFC is exclusively located in
somata and neuropil elements belonging to inhibitory neurons,
both in rodents and in humans [9,11,30]. Consequently, PPHT-
induced increases in PSA-NCAM expression in the mPFC should
affect primarily these inhibitory neurons rather than principal
neurons, which do not express PSA-NCAM [11]. In fact, PSA-
NCAM expressing interneurons in the mPFC express D2R and
dopaminergic fibers are frequently found in their vicinity [12].
PSA-NCAM expressing neuronal somata in the mPFC of adult
rats correspond to different interneuronal subpopulations (attend-
ing to their expression of different calcium binding proteins and
neuropeptides): the majority of these cells express CB, few of them
express CR and almost none of them expressed PV [9,11]. A very
similar neurochemical phenotype has been found in PSA-NCAM
expressing neurons in the mPFC of adult humans [30], mice
[11,31] and cats [32], with only minor differences in the
percentages across species. The number of PSA-NCAM express-
ing interneurons in this region is stable over lifetime in rats [10],
but pharmacological manipulations of monoaminergic neuro-
transmission (present work and [10]) can decrease or increase it,
indicating that inhibitory neurons in the mPFC can probably stop
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Perisomatic puncta on pyramidal neurons
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d GAD65/67 q *** q *** q ***
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% of PV puncta co-expressing SYN Q *** q *** q ***
No statistically significant differences (=) or statistically significant increases (q) or decreases (Q) on the parameters measured, when compared with control/control
group following the appropriate statistical analysis (see materials and methods section); p,0.05 (*), p,0.01 (**), p,0.001 (***).
Abbreviations: CBPs, Calcium-Binding Proteins; CB, calbindin-D28k; CR , calretinin; d, density (number of puncta or spines/mm of soma perimeter); GAD67, 67 kDa
isoform of the glutamate decarboxilase enzime, GAD65/67, both 65 and 67 kDa isoforms of the glutamate decarboxilase enzyme; NCAM, neural cell adhesion molecule;
PSA-NCAM, polysialylated form of the NCAM; PV, parvalbumin; SYN, synaptophysin.
doi:10.1371/journal.pone.0029516.t003
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PLoS ONE | www.plosone.org 8 December 2011 | Volume 6 | Issue 12 | e29516Figure 3. Quantification and confocal microscopic analysis of the neurochemical phenotype of PSA-NCAM expressing interneurons
in mPFC after PPHT treatment. (A) Graph showing statistically significant differences in the number of PSA-NCAM expressing somata from control
group after unpaired Student’s t-test; p,0.001 (***). (B) Graph representing the changes in the number of somata belonging to different interneuron
subpopulations (defined by the expression of the calcium-binding proteins CB, CR and PV) after PPHT treatment [p,0.01 (**); p,0.001 (***) after
unpaired Student’s expression] (C) Graph showing the percentages of PSA-NCAM expressing interneuron somata belonging to different interneuron
subpopulations. No statistically significant differences from control group were observed after unpaired Student’s t-tests (p.0.05 in all comparisons).
(D) Multipolar neuron expressing PSA-NCAM in dorsal Cingulate Cortex (Cg1) layer V observed under conventional light microscopy. (E) PSA-NCAM
interneuron in Cg1 layer V co-expressing CB. (F) PSA-NCAM/CR double labeled interneuron in ventral Cingulate Cortex (Cg2) layer V. (G) Lack of co-
D2R & PSA-NCAM Modulate mPFC Structural Plasticity
PLoS ONE | www.plosone.org 9 December 2011 | Volume 6 | Issue 12 | e29516expressing, express ‘‘de novo’’ or re-express PSA-NCAM.
Nevertheless, we have shown that the percentages of PSA-NCAM
expressing interneurons belonging to different interneuron sub-
populations did not change after D2R agonist treatment.
However, the total number of interneuron somata expressing
each of the three Calcium-binding proteins analyzed is increased
after PPHT treatment. These results are in agreement with those
describing a PPHT-induced increase of GAD67 expression and
indicate that the activity of different populations of interneurons
can be affected by PPHT.
localization between PSA-NCAM (G1) and PV (G2) expressing neurons in Cg1 layer III. E–G images are 2D projections of focal planes located 1 mm
apart. Scale bar: 10 mm. Insets in the images are 26enlarged views taken from single confocal planes of the areas marked with arrowheads.
doi:10.1371/journal.pone.0029516.g003
Figure 4. Panoramic views of the rat mPFC cortex and graphs showing the expression of PSA-NCAM (a–e), SYN (f–j), GAD67 (k–o)
and NCAM (p–t) in the mPFC neuropil after Endo-N or PPHT treatments and their combination. Three sections per animal were
examined under bright-field illumination, homogeneously lighted and digitalized using a CCD camera at 206 magnification. Grey levels were
converted to optical densities (OD) using Image J software (NIH). Detailed description of this method of quantification can be found in material and
methods S1. Note in panel c & d, the lack of PSA-NCAM expression in the cingulate cortex, but not in the striatum, demonstrating the effectiveness
of Endo-N treatment. Asterisks in bars indicate statistically significant differences between groups (see graph legend) after univariate repeated
measures ANOVA followed by multiple pair-wise comparisons with Bonferroni’s correction; p,0.05 (*), p,0.01 (**), p,0.001 (***). Scale bar: 100 mm.
doi:10.1371/journal.pone.0029516.g004
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PLoS ONE | www.plosone.org 10 December 2011 | Volume 6 | Issue 12 | e29516Figure 5. Confocal microscopic analysis of PSA-NCAM, GAD65/67, PV and SYN expressing puncta in the perisomatic region of
mPFC pyramidal neurons after Endo-N or PPHT treatments and their combination. Focal planes of pyramidal neuron somata
(immunolabeled for CaMKII-a) showing the changes in the perisomatic density of PSA-NCAM (a–b), GAD65/67 (d–g), PV (i–l) and SYN (n–q) expressing
puncta after the different treatments, as can be observed in graphs (c), (h), (m) and (r), respectively. (s–w) Focal planes and graph showing the
changes on the percentage of PV expressing puncta co-expressing SYN after treatment. Asterisks in bars indicate statistically significant differences
between groups (see graph legend) after unpaired Student’s t-test (c) or one-way ANOVA (h, m, r, w) followed by Bonferroni’s correction; p,0.05 (*),
p,0.01 (**), p,0.001 (***).
doi:10.1371/journal.pone.0029516.g005
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neurons in the mPFC of adult rats also seem to correspond to
inhibitory and synaptic elements, as it has been described before
for neocortical neuropil elements expressing this molecule [11].
Surprisingly, despite the fact that it is extremely rare to find this
molecule in neuronal somata expressing PV [9,11], we have found
that co-expression of PV and PSA-NCAM is common in
perisomatic puncta on pyramidal neurons. This suggests that in
PV expressing interneurons PSA-NCAM may have a restricted
expression pattern, similar to that of mature hippocampal granule
neurons, which only express it in their axons, but not in their
somata or dendrites [33]. Moreover, its expression in PV
expressing puncta may be regulated by the manipulation of
dopamine neurotransmission in the mPFC, as indicated by the
present data.
Given its anti-adhesive properties, PSA-NCAM expression in
neurons has been usually linked to plastic events, such as dendritic
or spine remodeling and synaptogenesis [6–8,34]. However, a
non-excluding insulating role for PSA-NCAM, preventing, totally
or partially, the establishment of synapses should not be discarded.
Figure 6. Schematic drawing of the hypothetic effects of PPHT and/or Endo-N administration in the perisomatic region of
pyramidal neurons and in the neuropil of the medial prefrontal cortex. Perisomatic region: PPHT induces the appearance of new
inhibitory contacts: some of them express PSA-NCAM (black asterisks), but some others may have already lost PSA-NCAM expression (red asterisks).
Expression of PSA-NCAM may also be induced in preexisting inhibitory contacts (red arrow). It is possible that some of these PSA-NCAM expressing
puncta were not functional synapses and this may be why we do not detect changes in the number of synaptophysin expressing puncta and there
are decreases in the percentage of parvalbumin positive puncta that co-express synaptophysin. Endo-N depletes PSA-NCAM from the perisomatic
region and promotes the maturation of contacts that previously expressed PSA-NCAM, inducing the expression of inhibitory markers (parvalbumin/
GAD) and/or synaptophysin (black arrows), leading also to an increase of the percentage of parvalbumin puncta co-expressing synaptophysin. When
PPHT is administered after Endo-N, most puncta remain stable, although some of them may continue with the maturation process initiated by
PSA depletion and/or promoted by PPHT (green arrows). Neuropil: Note that the proportion of PSA-NCAM expressing puncta is more reduced than
in the perisomatic region of pyramidal neurons and that many of these puncta do not correspond to synaptic boutons. PPHT induces the
appearance of inhibitory puncta; some of them express PSA-NCAM (black asterisks) and some of them may have already lost its expression (red
asterisks). Some of these newly generated structures may have matured faster than in the perisomatic region and have started to express
synaptophysin. Endo-N administration may have little impact on neuropil because of the low proportion of PSA-NCAM expressing puncta in this
region and because the nature of these puncta is different: most perisomatic puncta should correspond to presynaptic boutons contacting the
pyramidal cell body, while in the neuropil many of these structures correspond to dendritic and axonal processes and not to synaptic contacts. The
expression of inhibitory markers (parvalbumin/GAD) and/or synaptophysin would only be induced in some scarce puncta (black arrows). The
administration of PPHT after Endo-N does not produce any effect, because the presence of PSA-NCAM may be absolutely necessary to induce
the changes mediated by PPHT in this region.
doi:10.1371/journal.pone.0029516.g006
D2R & PSA-NCAM Modulate mPFC Structural Plasticity
PLoS ONE | www.plosone.org 12 December 2011 | Volume 6 | Issue 12 | e29516In fact, taking into account its steric effects [35], the addition of
PSA to NCAM in a synaptic contact should prevent or profoundly
affect normal neurotransmission. Consequently, the expression of
PSA-NCAM in certain neuropil elements and especially in
perisomatic puncta on pyramidal cells may indicate that these
structures are not establishing functional synaptic contacts. In
connection with this idea, we have recently found that PSA-
NCAM expressing interneurons have reduced synaptic input,
reduced spine density and are less arborized than neighboring
interneurons lacking PSA-NCAM, which suggests that they are
partially disconnected from cortical circuitry [11]. The effects of
PPHT on the expression of PSA-NCAM may have been produced
by an increase of the polysialylation on preexisting NCAM (before
its incorporation to the plasma membrane) or by the synthesis of
new NCAM that became polysialylated. Since we have not
detected changes in total NCAM expression, the first possibility is
less likely. Endo-N treatment also failed to modify NCAM
expression, suggesting that the removal of PSA does not affect
the synthesis of NCAM, at least at the time points analyzed in our
study.
Effects of PSA depletion from the mPFC
Removal of PSA from the mPFC completely blocks the effects
of PPHT treatment on SYN and GAD65/67 expression in the
neuropil. Consequently, the appearance of new structures
belonging to interneurons and new synapses (presumably inhib-
itory ones) may need the expression of PSA-NCAM. The anti-
adhesive properties of this molecule may favor the extension/
formation of neurites and synapses from certain interneurons in a
similar way to what has been described in hippocampal granule
neurons [36].
Although PSA depletion by itself does not affect the expression
of SYN and GAD65/67 in the mPFC neuropil, it induces
dramatic effects in the perisomatic region of pyramidal neurons,
increasing the density of perisomatic puncta expressing GAD65/
67, PV and SYN, as well as the percentage of PV puncta that co-
express SYN. A possible explanation for these effects is that the
removal of PSA from NCAM may activate some perisomatic
synapses, which were previously blocked by the presence of PSA.
Consequently, the expression of molecules related to active
inhibitory neurotransmission, such as SYN, GAD65/67 and PV,
is increased and more puncta become detectable. These results are
in agreement with a previous study on the developing visual
cortex, in which PSA depletion induced precocious maturation of
perisomatic innervation by basket interneurons, resulting in
enhanced inhibitory synaptic transmission [18]. Thus, the
presence of PSA-NCAM in control adult mPFC may act as a
regulator of perisomatic inhibitory innervation.
A puzzling aspect of our study is why the effects of PSA removal
on puncta expressing markers of general and inhibitory synapses
are important in the perisomatic region of pyramidal neurons, but
virtually absent in the neuropil of the mPFC. To understand these
differences, first it has to be considered that the density of puncta
expressing PSA is higher in the former region than in the latter.
Consequently, changes induced by PSA depletion will have a
higher impact and will be easily detected in the perisomatic region.
It is also important to consider that the nature of puncta is
different in these two regions. While most perisomatic puncta
should correspond to presynaptic boutons contacting the pyrami-
dal cell body, in the neuropil many of these structures correspond
to dendritic and axonal processes and not mainly to synaptic
contacts. Consequently, the impact of PSA depletion on proteins
associated to synapses should be more reduced. A scheme
depicting the hypothetic effects of the treatments used in our
study on the perisomatic region of pyramidal neurons and in the
neuropil of the mPFC is shown in figure 6.
The changes induced by PSA depletion or by alterations in the
degree of NCAM polysialylation, may not only be caused by the
regulation of NCAM adhesive properties, but also by the
influence of PSA on NCAM-mediated signaling (see [7] for
review). Moreover, interference on NCAM may also impair
dopaminergic neurotransmission, since NCAM regulates the
trafficking, internalization and degradation of D2R [37].
Interestingly, there is evidence for a relationship between
dysregulation of NCAM and its posttranslational modifications
and the neural abnormalities found in different mood disorders
[38]. Moreover, one of the enzymes responsible for NCAM
polysialylation is a candidate susceptibility gene for schizophrenia
and bipolar disorder [39,40] and PSA-NCAM expression is
altered in the brain of schizophrenics [41]. Our results showing
the involvement of PSA-NCAM in the plasticity induced by D2R
manipulation also support the idea that altered PSA-NCAM
expression may participate in the etiology of these psychiatric
disorders.
Supporting Information
Figure S1 Graphs showing the changes in the number of
PSA-NCAM immunoreactive neurons after PPHT treat-
ment. (A) Infralimbic cortex; (B) Prelimbic cortex; (C) Dorsal
cingulate cortex; (D) Ventral cingulate cortex. Asterisks in bars
indicate statistically significant differences from control group after
repeated measures ANOVA followed by multiple pair-wise
comparisons with Bonferroni’s correction; p,0.05 (*), p,0.01 (**),
p,0.001 (***). Roman numbers indicate cortical layers.
(TIF)
Figure S2 Graphs showing the changes in the number of
neurons expressing CB, CR or PV after PPHT treatment.
(A) Infralimbic cortex; (B) Prelimbic cortex; (C) Dorsal cingulate
cortex; (D) Ventral cingulate cortex. Asterisks in bars indicate
statistically significant differences from control group after
repeated measures ANOVA followed by multiple pair-wise
comparisons with Bonferroni’s correction; p,0.05 (*), p,0.01 (**),
p,0.001 (***).
(TIF)
Figure S3 Panoramic views of the rat mPFC cortex
showing the distribution of PSA-NCAM (B, F), SYN (C, G)
and GAD67 (D, H) immunoreactivity in the neuropil.
Pictures A–D show the infralimbic (IL) and prelimbic (PrL) regions
of the rat mPFC and pictures E–H, the dorsal (Cg1) and ventral
cingulate cortices (Cg2). (A, E) Nissl staining was used for
determining layer boundaries within mPFC regions, based on
cytoarchitectural differences across these layers. Roman numbers
indicate cortical layers. Scale bar: 200 mm.
(TIF)
Figure S4 Graphs representing the changes in PSA-
NCAM neuropil expression after Endo-N and/or PPHT
treatments. (A) Infralimbic cortex; (B) Prelimbic cortex; (C)
Dorsal cingulate cortex; (D) Ventral cingulate cortex. Asterisks in
bars indicate statistically significant differences between groups
(see graph legend) after univariate repeated measures ANOVA
followed by multiple pair-wise comparisons with Bonferroni’s
correction; p,0.05 (*), p,0.01 (**), p,0.001 (***). Roman
numbers indicate cortical layers.
(TIF)
Figure S5 Graphs showing the changes in SYN neuropil
expression after Endo-N and/or PPHT treatments. (A)
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PLoS ONE | www.plosone.org 13 December 2011 | Volume 6 | Issue 12 | e29516Infralimbic cortex; (B) Prelimbic cortex; (C) Dorsal cingulate
cortex; (D) Ventral cingulate cortex. Asterisks in bars indicate
statistically significant differences between groups (see graph
legend) after univariate repeated measures ANOVA followed by
multiple pair-wise comparisons with Bonferroni’s correction;
p,0.05 (*), p,0.01 (**), p,0.001 (***). Roman numbers indicate
cortical layers.
(TIF)
Figure S6 Graphs representing the changes in GAD67
neuropil expression after Endo-N and/or PPHT treat-
ments. (A) Infralimbic cortex; (B) Prelimbic cortex; (C) Dorsal
cingulate cortex; (D) Ventral cingulate cortex. Asterisks in bars
indicate statistically significant differences between groups (see
graph legend) after univariate repeated measures ANOVA
followed by multiple pair-wise comparisons with Bonferroni’s
correction; p,0.05 (*), p,0.01 (**), p,0.001 (***). Roman
numbers indicate cortical layers.
(TIF)
Table S1 Body weight analysis. Body weight data of all
experimental animals in the day of surgery (day 0), before the
onset of pharmacological treatment (day 7), in the middle of
pharmacological treatment (day 10) and at the end of the
experiment (day 14). Body weight differences across the different
time points (day 0, 7, 10 and 14) were calculated ant then analyzed
by one-way ANOVA tests (Inter-groups) followed, when appro-
priate, by multiple pair-wise comparisons with Bonferroni’s
correction. No statistically significant differences [n.s (p.0.05)]
or statistically significant differences [p,0.05(*), p,0.01 (**),
p,0.001 (***)] between groups.
(DOC)
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